Developer docs
API playgroundTry for free, no card

Search company profiles

Stipple Bio

Full company profile

uuid0002jq6

Namestring
Stipple Bio
Legal namestring
Stipple Bio, Inc
Websiteurl
stipple.bio
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Stipple Bio is a biotech company that focuses on advancing cellular profiling and target discovery using epitope-level resolution technologies. It develops proprietary platforms that analyze cellular interactions, enabling researchers to identify precise therapeutic targets for drug development. The company’s approach is particularly applied in oncology, where it aims to discover tumor-specific cell surface epitopes to create safer and more effective treatments. Its “Pointillist” platform is designed to map these epitopes with high precision, helping overcome limitations of traditional therapies such as off-target toxicity.

Short descriptiontext

Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, antibody drug conjugates, tumor-specific epitope discovery, cancer drug development, targeted biopharmaceuticals
Industry3 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Precision Oncology Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Commercialization
TypeOne Time License
Description

Pre-revenue biotechnology company. Revenue will be generated through commercialization of pipeline candidates including lead program STP-100, an Antibody Drug Conjugate for precision oncology. As a clinical-stage company, no product revenue is currently generated.

globenewswire.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Lonza partnership structured with upfront, clinical, regulatory, and commercial milestone payments plus royalties on net sales of resulting ADC products. Strategic partnerships may generate additional licensing revenue streams.

bioxconomy.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Stipple Bio develops precision oncology therapeutics by using its proprietary Pointillist Platform to identify tumor-specific cell surface epitopes that distinguish cancer cells from healthy tissue. The company is building a pipeline of epitope-directed medicines, with lead candidate STP-100, a novel Antibody Drug Conjugate (ADC), advancing toward Phase 1 clinical studies expected in early 2027. Its approach is designed to overcome the on-target/off-tumor toxicity that limits conventional targeted cancer therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Lead candidate STP-100 expected to enter clinical studies in early 2027
+1 more record
Product overview1 text field

Stipple Bio is a precision oncology biotechnology company built around its proprietary Pointillist Platform, which identifies tumor-specific cell surface epitopes for drug discovery. The company is developing a pipeline of next-generation precision oncology medicines, with its lead candidate STP-100, a novel Antibody Drug Conjugate (ADC), expected to enter clinical studies in early 2027. The Pointillist Platform enables epitope-level targeting that differentiates tumor cells from healthy tissue, addressing the therapeutic index limitations of conventional targeted therapies.

Product and service1 record
1STP-100
CategoryPrecision Oncology Therapeutics
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Lonza
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-04
Description

Multi-target licensing agreement granting Stipple Bio access to Lonza's clinically validated ADC technology platform including GlycoConnect conjugation technology, HydraSpace polar spacer technology, and toxSYN linker payload technologies. Lonza is eligible to receive upfront, clinical, regulatory, and commercial milestone payments plus royalties on net sales. Collaboration combines Stipple Bio's epitope discovery capabilities with Lonza's bioconjugation and manufacturing capabilities to advance precision oncology ADC therapies including lead program STP-100.

bioxconomy.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1CytomX Therapeutics
TypeDirect peer
Description

Clinical-stage oncology biotech developing Probody™-drug conjugates and other conditionally activated therapeutics. Directly comparable to Stipple Bio given shared focus on tumor-selective targeting, ADC/biologic modalities, and overlapping leadership pedigree (Stipple CEO and CBO are former CytomX executives).

2Bolt Biotherapeutics
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing next-generation ADCs and ISACs that combine tumor-targeting antibodies with immune stimulation. Closely comparable to Stipple Bio as a targeted oncology ADC platform company pursuing improved therapeutic index through novel conjugation approaches.

3Mersana Therapeutics
TypeDirect peer
Description

Clinical-stage company developing innovative ADCs with proprietary payload and linker platforms (Dolasynthen, Immunosynthen) for oncology. Highly comparable to Stipple Bio as an ADC-platform company focused on improving therapeutic index through novel chemistry.

4Pyxis Oncology
TypeDirect peer
Description

Clinical-stage oncology company building a pipeline of ADCs and immuno-oncology therapeutics with a focus on difficult-to-drug targets. Comparable to Stipple Bio as a precision oncology platform developing targeted therapeutics against tumor-selective antigens.

5ImmunoGen (AbbVie)
TypeBroad incumbent
Description

Pioneer in ADC technology with approved drug (Elahere) and broad clinical pipeline, now part of AbbVie. Comparable as the established incumbent in the ADC space against which Stipple Bio's epitope-targeted ADCs will compete for partnerships and clinical differentiation.

6ProfoundBio
TypeEmerging player
Description

Clinical-stage ADC platform company developing next-generation antibody-drug conjugates with proprietary linker-payload technology. Comparable to Stipple Bio as a similarly positioned emerging ADC developer pursuing improved therapeutic index through novel conjugation chemistry.

7Adagene
TypeEmerging player
Description

Clinical-stage oncology company leveraging AI-driven antibody discovery (POWER platform) to generate conditionally activated antibodies and bispecifics. Comparable to Stipple Bio as a platform-based oncology developer focused on tumor-selective targeting.

8Werewolf Therapeutics
TypeEmerging player
Description

Clinical-stage oncology company developing tumor-selective 'PREDATOR' therapeutics, including masked cytokines and ADCs. Comparable to Stipple Bio given shared focus on improving therapeutic index via tumor-selective activation and targeted oncology payloads.

9Compass Therapeutics
TypeEmerging player
Description

Clinical-stage oncology biotech developing a pipeline of bispecific antibodies and ADCs. Comparable to Stipple Bio as a clinical-stage targeted oncology platform with overlapping investor base and parallel modality focus.

10Black Diamond Therapeutics
TypeEmerging player
Description

Clinical-stage precision oncology company targeting allosteric mutations and difficult-to-drug oncology targets. Comparable to Stipple Bio as a target-discovery-driven precision oncology platform pursuing differentiated therapeutic concepts.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stipple Bio

Precision Oncology Therapeuticsstipple.bio

Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution.

What Stipple Bio does

Stipple Bio is a biotech company that focuses on advancing cellular profiling and target discovery using epitope-level resolution technologies. It develops proprietary platforms that analyze cellular interactions, enabling researchers to identify precise therapeutic targets for drug development. The company’s approach is particularly applied in oncology, where it aims to discover tumor-specific cell surface epitopes to create safer and more effective treatments. Its “Pointillist” platform is designed to map these epitopes with high precision, helping overcome limitations of traditional therapies such as off-target toxicity.

Stipple Bio firmographics

Firmographics
Name
Stipple Bio
Legal name
Stipple Bio, Inc
Website
https://stipple.bio
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution.
Ownership category
akta.pro rank

Stipple Bio industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision oncology therapeutics
  • Antibody drug conjugates
  • Tumor-specific epitope discovery
  • Cancer drug development
  • Targeted biopharmaceuticals

Where Stipple Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Stipple Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Others

Revenue model

  1. Drug Commercialization: Pre-revenue biotechnology company. Revenue will be generated through commercialization of pipeline candidates including lead program STP-100, an Antibody Drug Conjugate for precision oncology. As a clinical-stage company, no product revenue is currently generated.
  2. Licensing and Milestone Payments: Lonza partnership structured with upfront, clinical, regulatory, and commercial milestone payments plus royalties on net sales of resulting ADC products. Strategic partnerships may generate additional licensing revenue streams.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Stipple Bio product offering

Product offering

Core offering

Stipple Bio develops precision oncology therapeutics by using its proprietary Pointillist Platform to identify tumor-specific cell surface epitopes that distinguish cancer cells from healthy tissue. The company is building a pipeline of epitope-directed medicines, with lead candidate STP-100, a novel Antibody Drug Conjugate (ADC), advancing toward Phase 1 clinical studies expected in early 2027. Its approach is designed to overcome the on-target/off-tumor toxicity that limits conventional targeted cancer therapies.

Product overview

Stipple Bio is a precision oncology biotechnology company built around its proprietary Pointillist Platform, which identifies tumor-specific cell surface epitopes for drug discovery. The company is developing a pipeline of next-generation precision oncology medicines, with its lead candidate STP-100, a novel Antibody Drug Conjugate (ADC), expected to enter clinical studies in early 2027. The Pointillist Platform enables epitope-level targeting that differentiates tumor cells from healthy tissue, addressing the therapeutic index limitations of conventional targeted therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • STP-100

Quantifiable outcome

  • Lead candidate STP-100 expected to enter clinical studies in early 2027
  • +1 more outcomes

Companies that use Stipple Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Stipple Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Stipple Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • LonzacoreTechnology or Integration · 4 June 2026Multi-target licensing agreement granting Stipple Bio access to Lonza's clinically validated ADC technology platform including GlycoConnect conjugation technology, HydraSpace polar spacer technology, and toxSYN linker payload technologies. Lonza is eligible to receive upfront, clinical, regulatory, and commercial milestone payments plus royalties on net sales. Collaboration combines Stipple Bio's epitope discovery capabilities with Lonza's bioconjugation and manufacturing capabilities to advance precision oncology ADC therapies including lead program STP-100.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Stipple Bio competitors and assessment

Company assessment

Direct peers

  • CytomX Therapeutics: Clinical-stage oncology biotech developing Probody™-drug conjugates and other conditionally activated therapeutics. Directly comparable to Stipple Bio given shared focus on tumor-selective targeting, ADC/biologic modalities, and overlapping leadership pedigree (Stipple CEO and CBO are former CytomX executives).
  • Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing next-generation ADCs and ISACs that combine tumor-targeting antibodies with immune stimulation. Closely comparable to Stipple Bio as a targeted oncology ADC platform company pursuing improved therapeutic index through novel conjugation approaches.
  • Mersana Therapeutics: Clinical-stage company developing innovative ADCs with proprietary payload and linker platforms (Dolasynthen, Immunosynthen) for oncology. Highly comparable to Stipple Bio as an ADC-platform company focused on improving therapeutic index through novel chemistry.
  • Pyxis Oncology: Clinical-stage oncology company building a pipeline of ADCs and immuno-oncology therapeutics with a focus on difficult-to-drug targets. Comparable to Stipple Bio as a precision oncology platform developing targeted therapeutics against tumor-selective antigens.

Broad incumbents

  • ImmunoGen (AbbVie): Pioneer in ADC technology with approved drug (Elahere) and broad clinical pipeline, now part of AbbVie. Comparable as the established incumbent in the ADC space against which Stipple Bio's epitope-targeted ADCs will compete for partnerships and clinical differentiation.

Emerging players

  • ProfoundBio: Clinical-stage ADC platform company developing next-generation antibody-drug conjugates with proprietary linker-payload technology. Comparable to Stipple Bio as a similarly positioned emerging ADC developer pursuing improved therapeutic index through novel conjugation chemistry.
  • Adagene: Clinical-stage oncology company leveraging AI-driven antibody discovery (POWER platform) to generate conditionally activated antibodies and bispecifics. Comparable to Stipple Bio as a platform-based oncology developer focused on tumor-selective targeting.
  • Werewolf Therapeutics: Clinical-stage oncology company developing tumor-selective 'PREDATOR' therapeutics, including masked cytokines and ADCs. Comparable to Stipple Bio given shared focus on improving therapeutic index via tumor-selective activation and targeted oncology payloads.
  • Compass Therapeutics: Clinical-stage oncology biotech developing a pipeline of bispecific antibodies and ADCs. Comparable to Stipple Bio as a clinical-stage targeted oncology platform with overlapping investor base and parallel modality focus.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company targeting allosteric mutations and difficult-to-drug oncology targets. Comparable to Stipple Bio as a target-discovery-driven precision oncology platform pursuing differentiated therapeutic concepts.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Stipple Bio social profiles

Digital presence

Stipple Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stipple Bio leadership team

Management profile

Number of profiles

Profiles6 records

Stipple Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stipple Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stipple Bio

What does Stipple Bio do?

Stipple Bio develops precision oncology therapeutics by using its proprietary Pointillist Platform to identify tumor-specific cell surface epitopes that distinguish cancer cells from healthy tissue. The company is building a pipeline of epitope-directed medicines, with lead candidate STP-100, a novel Antibody Drug Conjugate (ADC), advancing toward Phase 1 clinical studies expected in early 2027. Its approach is designed to overcome the on-target/off-tumor toxicity that limits conventional targeted cancer therapies.

Is Stipple Bio a public or private company?

Stipple Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Stipple Bio founded?

Stipple Bio was founded in 2022. It employs 11 to 50 people.

Where is Stipple Bio based?

Stipple Bio is headquartered in Cambridge, United States, in the North America region.

How does Stipple Bio make money?

Two revenue lines are on record. Drug Commercialization is the primary driver. The others are licensing and Milestone Payments.

Who are Stipple Bio's main competitors?

Direct peers on record are CytomX Therapeutics, Bolt Biotherapeutics, Mersana Therapeutics and Pyxis Oncology. ImmunoGen (AbbVie) is listed as a broad incumbent. Emerging players are ProfoundBio, Adagene, Werewolf Therapeutics, Compass Therapeutics and Black Diamond Therapeutics.

Does Stipple Bio have an API?

No public API is recorded for Stipple Bio.

What industry is Stipple Bio in?

Stipple Bio's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaLilly inks oncology licensing deal worth up to $5.9B with Stipple BioEli Lilly signed an exclusive global licensing agreement with Stipple Bio to develop cancer drugs, worth up to $5.9B. The deal includes an upfront payment, equity investment, and milestone payments, with Lilly receiving exclusive worldwide rights. The agreement follows Lilly's acquisition of Calytrix Bio for up to $1.5B.Pharmaceutical TechnologyEli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio - Pharmaceutical TechnologyEli Lilly signed an oncology research collaboration and license agreement with Stipple Bio worth up to $5.9bn. The deal includes an upfront payment, equity investment, and tiered royalties, with Lilly gaining worldwide rights. Stipple plans a Phase I clinical trial for an antibody-drug conjugate in early 2027.BioSpaceLilly pens another deal, inking up to $5.9B oncology pact with StippleEli Lilly announced a licensing deal with Stipple Bio for its Pointillist Platform, potentially building to $5.9 billion in milestones. The deal gives Lilly exclusive worldwide rights, while Stipple receives an upfront payment and equity. This follows Lilly's up to $1.5 billion buyout of Calytrix Bio.The Pharma LetterStipple Bio strikes $5.9B deal with LillyStipple Bio announced a multi-target multi-modality strategic research collaboration and license agreement with Eli Lilly. The deal involves Stipple's Pointillist Platform to discover tumor-specific cell surface epitope binders, which Lilly will combine with its oncology technologies. The agreement aims to advance high therapeutic index compounds across multiple modalities.FierceBiotechLilly signs $5.9B deal with Stipple to unlock oncology targetsEli Lilly signed a $5.9 billion deal with Stipple Bio to develop oncology drugs targeting tumor-specific epitopes. The partnership includes an upfront payment and equity investment, with milestones that could increase value to $5.9 billion plus royalties. Stipple raised $100 million in April, extending its runway to 2029.Endpoints NewsLilly strikes up to $5.9B cancer deal with Stipple BioEli Lilly has partnered with Stipple Bio to develop new cancer treatments in a multibillion-dollar deal. The collaboration involves the Cambridge, MA-based startup, with the deal's value not disclosed.The Pharma LetterStipple Bio names Roland Gendron chief business officerUS precision oncology biotech Stipple Bio has appointed Roland Gendron as its chief business officer to support the advancement of its lead candidate STP-100 into early clinical studies. Gendron joins from Merus, the Dutch biotech company that was acquired by Danish biotech Genmab in an $8 billion deal centered on the late-stage oncology asset petosemtamab.BioSpaceStipple Bio Appoints Biopharma Business Development Leader Roland Gendron as Chief Business OfficerStipple Bio appointed Roland Gendron as Chief Business Officer, bringing over 25 years of biopharmaceutical experience. He previously led business development at Merus, where his work contributed to an $8 billion acquisition by GenMab. He will lead corporate development, strategic partnerships, and pipeline expansion.BioXconomyLonza and Stipple Bio strike deal for precision oncology ADCsLonza and Stipple Bio have entered into a multi-target agreement granting Stipple access to Lonza's clinically validated ADC technology platform, including GlycoConnect conjugation, HydraSpace polar spacer, and toxSYN linker payload technologies. Stipple Bio will receive these technologies to support its precision oncology pipeline, with its lead candidate STP-100 expected to enter clinical studies in early 2027. Lonza is eligible to receive upfront, clinical, regulatory, and commercial milestone payments, plus royalties on net sales of resulting products.The Pharma LetterStipple Bio taps Lonza platform to advance ADC pipelineStipple Bio signed a multi-target licensing agreement with Lonza to access its ADC platform, including GlycoConnect, HydraSpace, and toxSYN. The deal covers its lead candidate STP-100, with financial terms undisclosed but including upfront, milestone, and royalty payments.